Home > Drugs A – Z > Rilpivirine (By mouth)

Rilpivirine (By mouth)

Treats HIV infection. This medicine does not cure HIV or AIDS, but it may slow the progress of the disease.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Rilpivirine is used to treat human immunodeficiency virus (HIV) infection. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). This medicine is usually given to patients who have not received any HIV treatment in the past. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor. This medicine will not cure HIV infection or AIDS. It works by lowering the amount of HIV… Read more
Brand names include
Edurant
Drug classes About this
Antiretroviral Agent
Combinations including this drug

What works? Research summarized

Evidence reviews

Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis

OBJECTIVE: The aim of this study was to determine the effectiveness and safety of rilpivirine in treatment-naive adults infected with HIV-1.

Treatments for Patients with Genotype 1 Chronic Hepatitis C: A Review of Evidence-based Guidelines [Internet]

Approximately 242,000 Canadians are infected with the hepatitis C virus (HCV), although there are believed to be a number of infected individuals who are unaware that they have HCV. Of those infected, approximately 25% clear infection spontaneously (range 15% to 45%) and the remainder develop chronic hepatitis C (CHC). There are six genotypes and treatment strategy tends to differ depending on genotype.

48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis

BACKGROUND: A network meta-analysis can provide estimates of relative efficacy for treatments not directly studied in head-to-head randomized controlled trials. We estimated the relative efficacy and safety of dolutegravir (DTG) versus third agents currently recommended by guidelines, including ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV), cobicistat-boosted elvitegravir (EVG/c), ritonavir-boosted lopinavir (LPV/r), raltegravir (RAL), and rilpivirine (RPV), in treatment-naive HIV-1-infected patients.

Summaries for consumers

Rilpivirine (Edurant, Eviplera) for HIV-infections: Initial treatment: Rilpivirine in combination with other agents

The agent efavirenz in combination with two other agents is the common initial treatment for patients with HIV. Emtricitabine and tenofovir are two possible agents for this treatment.In early 2012, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) assessed the benefit of rilpivirine (trade name: Edurant) in combination with two other agents compared to efavirenz in combination with two other agents. 815 patients were included in the studies. About three quarters of them received the combination of emtricitabine and tenofovir, about one quarter received zidovudine and lamivudine. Only a few patients were given abacavir and lamivudine.

Rilpivirine (Edurant, Eviplera) for HIV-infections: Initial treatment: Rilpivirine in fixed combination with emtricitabine/tenofovir

The agent efavirenz in combination with two other agents is the common initial treatment for patients with HIV. Emtricitabine and tenofovir are two possible agents for this treatment.In early 2012, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) assessed the benefit of rilpivirine in combination with emtricitabine/tenofovir (trade name: Eviplera) in comparison to efavirenz in combination with emtricitabine/tenofovir. The assessment was based on three studies.

Rilpivirine (Edurant, Eviplera) for HIV-infections: Overview

Rilpivirine has been approved in Germany since November 2011 as a single agent (trade name: Edurant) and in a fixed combination with emtricitabine and tenofovir (trade name: Eviplera) for treatment of HIV type 1 infection in some adults.

PubMed Health Blog...

read all...